Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System | ||||
By: PR Newswire Association LLC. - 26 Mar 2024 | Back to overview list |
|||
Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams. "An extensive number of peer-reviewed scientific manuscripts have been published reporting on CyberKnife prostate SBRT efficacy and tolerability. This most recent RSS data demonstrates the ongoing interest in advancing patient care with the system, based on its ability to deliver the precision and accuracy necessary to not just help men to survive prostate cancer but also to have a meaningful quality of life post treatment," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray. The CyberKnife System enables treatment of prostate cancer using a form of radiation therapy called stereotactic body radiation therapy (SBRT) - very precise, high doses of radiation are delivered over a shorter duration than traditional treatments. The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT. CyberKnife Platform for Prostate Cancer: The CyberKnife platform offers an effective treatment option for prostate tumors in 4-5 sessions, compared to conventional radiation therapy that usually requires approximately 30-40 sessions over 8-10 weeks. Data presented at the RSS meeting showed its ability to:
The prostate gland can move unpredictably throughout the course of treatment. In fact, the prostate has been documented to move as much as 10 mm in as little as 30 seconds due to normal patient bodily functions – such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure3,4,5,6, making the ability to track, detect and correct for motion critically important. The CyberKnife System, using advanced imaging and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery, with the Accuray proprietary Synchrony® technology, can track the tumor and continually verify its position, automatically correcting and adapting the radiation beam position for even the slightest movement. For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time. About Accuray Safe Harbor Statement Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html SOURCE Accuray Incorporated |
||||
|
||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |